- recruitingTherapeutic confirmatory (Phase III)
Phase 3, Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects
This study is looking into a new medication called Tinlarebant for young people with Stargardt disease. It aims to see if the medication is safe and can slow down the development of the condition over about two years, compared to a dummy treatment.
France · Netherlands · Belgium - recruitingPHASE1, PHASE2
A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)
This study is testing a new treatment, AAVB-039, for Stargardt disease, an eye condition. Researchers want to see if it's safe and how well it works. It involves a single injection into the eye. It's for people with Stargardt disease caused by specific gene changes.
United States · Norway · United Kingdom - recruiting
An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene
This study looks closely at how Stargardt Disease type 1 (STGD1) changes over time. Researchers want to understand the disease better by watching people who have it. This will help them design better studies in the future to test new treatments for Stargardt.
United States · Germany · United Kingdom - authorisedPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2, First-in-Human, Open-label, Assessor-Masked, Randomized, Controlled, Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects with Stargardt Disease (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ATP Binding Cassette Subfamily A Member 4 (ABCA4) Gene (ASTRA).
This study is testing a new treatment called SB-007 for Stargardt disease, an eye condition that affects vision. It's the first time this treatment is being given to people, and researchers want to see if it's safe and how well it works.
Germany · Belgium - authorisedTherapeutic confirmatory (Phase III)
An Open-Label, Single-Arm, 3-Year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Subjects with Stargardt Disease
This study is looking at a new medicine called tinlarebant (LBS-008) for Stargardt Disease. It's a 3-year extension study to see if the medicine is safe and how well people tolerate it over time. Researchers will check for changes in eye health using special photographs.
Netherlands · France · Belgium